Clinical trials
4 active studies led by Renalytix AI, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Renalytix AI, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public records show Renalytix AI, Inc. in 4 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Renalytix AI, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
4 active studies led by Renalytix AI, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Renalytix AI, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Renalytix AI, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Renalytix AI, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Renalytix AI, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Renalytix AI, Inc. is in.
Stories on the topics Renalytix AI, Inc. works in.
2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack…
Read
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read